Data from the phase 1 portion of the combination of evorpacept + azacitidine for patients with higher-risk MDS demonstrated marrow CR in one out of five patients with TP53-mutated disease; the phase 2 portion is ongoing [97]. This evidence concerns the gene TP53 and myelodysplastic syndrome.